ViiV Healthcare
The purpose of this study is to identify 1 or more doses of parenterally administered VH4524184 that are safe, well tolerated and yield a PK drug exposure profile necessary to deliver a long-acting antiretroviral therapy for the treatment of HIV-1 infection.
Inclusion Criteria: Age -Participant must be 18 to 55 years of age inclusive, at the time of signing the informed consent. Type of Participant and Characteristics * Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring. * Participants who are able to understand and comply with protocol requirements and timetables, instructions, and protocol-stated restrictions. Weight -Body weight ≥50.0 kg (110 lbs) for men and ≥45.0 kg (99 lbs) for women and body mass index within the range 18.5 t…
VH4524184 to be taken orally.
VH4524184 LAI Formulation A administered subcutaneously.
Placebo Formulation A administered subcutaneously.
rHuPH20 administered subcutaneously.
VH4524184 LAI Formulation B administered subcutaneously.
Placebo Formulation B administered subcutaneously.
VH4524184 LAI Formulation A administered intramuscularly.
Placebo Formulation A administered intramuscularly.
VH4524184 LAI Formulation B administered intramuscularly.
Placebo Formulation B administered intramuscularly.